Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Cervical Cancer

Cervical Cancer

19 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Cervical Cancer

163 trials tracked for Cervical Cancer: 32 in phase 3 or 4 and 15 with published results. The most-cited published study has 1504 citations.

163Trials tracked
32Phase 3 & 4
0Recruiting
15With published results
Phase distribution
Phase 4 5 Phase 3 27 Phase 2 63 Phase 1 14 Other / NA 54
  1. Phase 3 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed · 1,504 cited
  2. Phase 3 Study of Cemiplimab in Adults With Cervical Cancer Completed · 428 cited
  3. Phase 3 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Completed · 369 cited
  4. Phase 3 Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) Completed · 364 cited
  5. Phase 3 Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) Completed · 245 cited
  6. Phase 3 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Completed · 194 cited
Show 44 more trials
  1. Phase 3 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer Completed · 165 cited
  2. Phase 4 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed · 112 cited
  3. Phase 3 Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Completed · 41 cited
  4. Phase 3 Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) Completed · 40 cited
  5. Phase 3 Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls Completed · 22 cited
  6. Phase 3 Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial Completed · 8 cited
  7. Phase 4 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed · 7 cited
  8. Phase 3 A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213) Completed · 4 cited
  9. Phase 3 Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017) Completed · 4 cited
  10. Phase 4 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Completed
  11. Phase 4 Alternate Dosing Schedules Study for HPV Vaccine Completed
  12. Phase 4 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed
  13. Phase 3 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed
  14. Phase 3 Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer Completed
  15. Phase 3 Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix Completed
  16. Phase 3 Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation Completed
  17. Phase 3 Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Completed
  18. Phase 3 Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer Completed
  19. Phase 3 A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) Completed
  20. Phase 3 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) Completed
  21. Phase 3 Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016) Completed
  22. Phase 3 Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015) Completed
  23. Phase 3 Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Completed
  24. Phase 3 A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) Completed
  25. Phase 3 Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants Completed
  26. Phase 3 Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix Completed
  27. Phase 2 Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer Completed
  28. Phase 2 A Study of Patients Receiving High-Dose Rate Brachytherapy Completed
  29. Phase 2 Bupropion in Helping Adults Stop Smoking Completed
  30. Phase 2 Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. Completed
  31. Phase 2 Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer Completed
  32. Phase 2 Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy Completed
  33. Phase 2 Irinotecan Study For Cervical Cancer Completed
  34. Phase 2 Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer Completed
  35. Phase 2 Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer Completed
  36. Phase 2 Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium Completed
  37. Phase 2 Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer Completed
  38. Phase 2 A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer Completed
  39. Phase 2 Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix Completed
  40. Phase 2 Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers Completed
  41. Phase 2 Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Completed
  42. Phase 2 T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive Completed
  43. Phase 2 Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer Completed
  44. Phase 2 Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers Completed

Showing the 50 most-cited and recently-updated of 163 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Cervical Cancer: what the trials found

Pembrolizumab has demonstrated significant improvements in progression-free survival (PFS) for cervical cancer patients. In one study, PFS was significantly higher compared to the control group as assessed by both investigator and blinded independent central review (BICR) 1. Another trial confirmed superior outcomes for Pembrolizumab across various cohorts, including those with a Programmed Cell Death-Ligand 1 (PD-L1) combined positive score (CPS) of ≥1 or ≥10 11.

Cemiplimab showed statistically significant improvements in both overall survival (OS) and progression-free survival (PFS) compared to standard treatments, with notable benefits observed specifically within the squamous cell carcinoma (SCC) population 9. Tisotumab vedotin also demonstrated superior OS, PFS, and confirmed objective response rates (ORR) compared to alternative therapies 13.

Several vaccines have been evaluated for cervical cancer prevention. Quadrivalent HPV vaccines (types 6, 11, 16, and 18) were shown to produce high seropositivity for types 16 and 18 at 36 months 17, while the 9vHPV vaccine achieved 100% seroconversion across multiple HPV types by month 7 19. Other vaccines including V501 [4, 18] and V503 15 demonstrated high geometric mean titers (GMTs) for anti-HPV antibodies.

Chemotherapeutic agents such as Carboplatin [12, 21] and Cisplatin [14, 20] are established in the treatment landscape. Additionally, standard radiation therapy was evaluated regarding toxicity; while some differences were noted in acute gastrointestinal and urinary toxicity scores, the percentage of patients with high-grade GI toxicity did not differ significantly from controls 10.

Recent results — preliminary, needs further review

  • TA-CIN (arm) is currently under investigation in a Phase 1 trial 2.

For the clinician treating this condition

  • Pembrolizumab and Cemiplimab are supported by evidence showing significant improvements in progression-free survival and overall survival [1, 9, 11].
  • Tisotumab vedotin is associated with superior objective response rates and progression-free survival compared to standard treatments 13.
  • Multiple HPV vaccines (including quadrivalent and 9vHPV) demonstrate high seroconversion and immunogenicity against major oncogenic types [17, 19].

AI synthesis of 9 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review links microbiome dysbiosis to gynecological cancer pathogenesis and potential therapeutic applications
OB/GYN & Women's Health Sys. Review
Narrative review links microbiome dysbiosis to gynecological cancer pathogenesis and potential therapeutic applications Microbiome changes may help explain how gynecological cancers start and grow
This narrative review examines the role of the human microbiome in gynecological malignancies, including cervical, ovarian, endometrial, vul…
New review suggests microbiome shifts could be key to understanding gynecological cancers, opening doors for better prevention and treatment…
Frontiers Apr 23, 2026
Network meta-analysis of immunotherapy for persistent, recurrent, or metastatic cervical cancer
Drug Pipeline Meta-analysis
Network meta-analysis of immunotherapy for persistent, recurrent, or metastatic cervical cancer Do newer immunotherapies help people with advanced cervical cancer live longer?
This systematic review and network meta-analysis of phase III trials synthesized evidence on first-line immunotherapy regimens for persisten…
Newer immunotherapy combinations help people with advanced cervical cancer live longer and shrink tumors better than standard chemotherapy a…
Frontiers Apr 19, 2026
Systematic review examines innate immune recognition and PRR activation in HPV infection and cervical cancer progression
Infectious Disease Sys. Review
Systematic review examines innate immune recognition and PRR activation in HPV infection and cervical cancer progression How HPV Outsmarts Your Body's First Line of Defense
This mini-review synthesizes evidence regarding innate immune recognition, pattern recognition receptor activation, and HPV evasion strategi…
HPV evades the immune system by silencing its alarms, fueling cervical cancer and pointing to new ways to prevent it.
Frontiers Apr 15, 2026
Meta-analysis of NHPI populations shows low pooled Pap testing and HPV vaccine initiation rates with high treatment disparities
Infectious Disease Meta-analysis
Meta-analysis of NHPI populations shows low pooled Pap testing and HPV vaccine initiation rates with high treatment disparities Imagine a cancer we know how to prevent. A simple test can catch it early. A vaccine can stop it before it starts
This systematic review and meta-analysis evaluated cervical cancer prevention metrics and treatment disparities in Native Hawaiian and Pacif…
This research uncovers a severe and life-threatening inequity in cancer care for a community often overlooked in health data.
Apr 10, 2026
Tumor budding associates with adverse clinicopathological features and reduced overall survival in cervical and endometrial cancer
Oncology Meta-analysis
Tumor budding associates with adverse clinicopathological features and reduced overall survival in cervical and endometrial cancer Tumor Budding Linked to Worse Outcomes in Cervical and Endometrial Cancer
This Bayesian meta-analysis of 18 observational cohort studies involving 3320 patients with cervical or endometrial cancer evaluated the pro…
Small clusters of cells breaking away from cervical and endometrial tumors signal more aggressive disease and worse survival outcomes.
Apr 9, 2026
Meta-analysis finds [68Ga]Ga-FAPI PET shows high diagnostic accuracy for gynecologic cancers
Oncology Meta-analysis
Meta-analysis finds [68Ga]Ga-FAPI PET shows high diagnostic accuracy for gynecologic cancers Could a new scan spot breast and ovarian cancer tumors better than the standard test?
A meta-analysis of 253 females with breast, ovarian, and cervical cancers compared [68Ga]Ga-FAPI PET to [18F]F-FDG PET imaging.
A new scan using a different tracer finds breast, ovarian, and cervical cancer tumors and spread much better than the standard test doctors …
Apr 9, 2026
HPV cfDNA testing shows high specificity but moderate sensitivity for cervical cancer detection
OB/GYN & Women's Health Meta-analysis
HPV cfDNA testing shows high specificity but moderate sensitivity for cervical cancer detection Blood test for HPV DNA shows promise for monitoring cervical cancer after treatment
A meta-analysis of 20 studies in HPV-positive cervical cancer patients found HPV cfDNA testing had pooled sensitivity of 0.47 and specificit…
A review of 20 studies found that a blood test looking for HPV DNA was very specific for detecting cervical cancer, but it missed about half…
Apr 8, 2026

Questions about Cervical Cancer

How does innate immune recognition affect the progression of Cervical Cancer and HPV?

HPV evades innate immune detection by suppressing PRR signaling and NLRP3 inflammasome, enabling persistent infection and cervical cancer progression.

Full answer →